REG - Creo Medical Group - Extension of Retail Offer Closing Date

Creo MedicalAnnouncement

04/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241004:nRSD9065Ga&default-theme=true

RNS Number : 9065G  Creo Medical Group PLC  04 October 2024

THIS ANNOUNCEMENT, INLCUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED
AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR
IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW
ZEALAND, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, JAPAN
OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION
WOULD BE UNLAWFUL.

 

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS
RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO,
AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING
WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL
PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF CREO
MEDICAL GROUP PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS
ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN
ONLY BY SUCH PERSONS.

 

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE
OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICIATION
OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SECURITIES OF CREO MEDICAL GROUP
PLC.

 

 

Creo Medical Group plc

("Creo" or the "Company")

 

Extension of Retail Offer Closing Date

 

Further to the announcement made on 30 September 2024 (RNS No 3043G) regarding
the Retail Offer, the Company announces that it is extending the time allowed
for existing retail shareholders to participate in the Retail Offer.

 

Under the revised timetable, the Retail Offer will now close at 4.30 p.m. on
17 October 2024 (previously 4.30 p.m. on 7 October). No other changes to the
timetable have been made.

 

The change in timetable does not impact applications already made in the
Retail Offer, and these continue to have effect and remain binding.

 

Revised Expected Timetable for the Fundraising

 

 Latest time and date for receipt of Forms of Proxy and CREST voting             10.00 a.m. on 16 October 2024
 instructions
 Closing of the Retail Offer and announcement of the result of the Retail Offer  4.30 p.m. on 17 October 2024
 General Meeting                                                                 10.00 a.m. on 18 October 2024
 Results of the General Meeting announced                                        18 October 2024
 Admission of the New Ordinary Shares to trading on AIM and commencement of      8.00 a.m. on 21 October 2024
 dealings
 Where applicable, expected date for CREST accounts to be credited in respect    8.00 a.m. on 21 October 2024
 of New Ordinary Shares in uncertificated form
 Where applicable, expected date for despatch of definitive share certificates   By 3 November 2024
 for New Ordinary Shares in certificated form

 

For further information, please visit www.creomedical.com
(http://www.creomedical.com/)  or contact:

 

 Creo Medical Group plc                                   www.creomedical.com (http://www.creomedical.com/)
 Richard Rees (CFO)                                       +44 (0)1291 606 005

 Cavendish Capital Markets Limited

 (Nominated Adviser, Joint Bookrunner and Joint Broker)   +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume / George Lawson (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Bookrunner and Joint Broker)       +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 William Baunton (ECM)

 Walbrook PR Ltd                                          Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Sam Allen /                               Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Phillip Marriage                                         +44 (0)7867 984 082

 

Further information on the Company can be found on its website at:
https://www.creomedical.com/en/investors/
(https://www.creomedical.com/en/investors/)

 

The Company's LEI is 213800H188ZDCWWXFA21

 

This announcement should be read in its entirety. In particular, the
information in the "Important Notices" section of the announcement should be
read and understood.

 

Important Notices

The Retail Offer is only open to investors in the United Kingdom who fall
within Article 43 of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (which includes an existing member of the
Company).

 

This announcement and the information contained herein is not for release,
publication or distribution, directly or indirectly, in whole or in part, in
or into or from the United States (including its territories and possessions,
any state of the United States and the District of Columbia (the "United
States" or "US")), Australia, Canada, Japan, the Republic of Ireland, the
Republic of South Africa, New Zealand or any other jurisdiction where to do so
might constitute a violation of the relevant laws or regulations of such
jurisdiction.

 

The Retail Offer Shares have not been and will not be registered under the US
Securities Act of 1933, as amended (the "US Securities Act") or under the
applicable state securities laws of the United States and may not be offered
or sold directly or indirectly in or into the United States or to or for the
account or benefit of any US person (within the meaning of Regulation S under
the US Securities Act) (a "US Person"). No public offering of the Retail
Offer Shares is being made in the United States. The Retail Offer Shares are
being offered and sold outside the United States in "offshore transactions",
as defined in, and in compliance with, Regulation S under the US Securities
Act. In addition, the Company has not been, and will not be, registered under
the US Investment Company Act of 1940, as amended.

 

This announcement does not constitute an offer to sell or issue or a
solicitation of an offer to buy or subscribe for Retail Offer Shares in the
United States, Australia, Canada, New Zealand, Japan, the Republic of Ireland,
the Republic of South Africa, New Zealand or any other jurisdiction in which
such offer or solicitation is or may be unlawful. No public offer of the
securities referred to herein is being made in any such jurisdiction.

 

The distribution of this announcement may be restricted by law in certain
jurisdictions and persons into whose possession any document or other
information referred to herein comes should inform themselves about and
observe any such restriction. Any failure to comply with these restrictions
may constitute a violation of the securities laws of any such jurisdiction.

 

Each of Cavendish and Numis Securities Limited (t/a Deutsche Numis) ("Deutsche
Numis") is authorised and regulated in the United Kingdom by the Financial
Conduct Authority is acting exclusively for the Company and for no-one else
and will not regard any other person (whether or not a recipient of this
announcement) as its client in relation to the Retail Offer and will not be
responsible to anyone other than the Company for providing the protections
afforded to its clients, nor for providing advice in connection with the
Retail Offer, Admission and the other arrangements referred to in this
announcement.

 

The value of Ordinary Shares and the income from them is not guaranteed and
can fall as well as rise due to stock market and currency movements. When you
sell your investment, you may get back less than you originally invested.
Figures refer to past performance and past performance is not a reliable
indicator of future results. Returns may increase or decrease as a result of
currency fluctuations.

 

Certain statements in this announcement are forward-looking statements which
are based on the Company's expectations, intentions and projections regarding
its future performance, anticipated events or trends and other matters that
are not historical facts. These forward-looking statements, which may use
words such as "aim", "anticipate", "believe", "intend", "estimate", "expect"
and words of similar meaning, include all matters that are not historical
facts. These forward-looking statements involve risks, assumptions and
uncertainties that could cause the actual results of operations, financial
condition, liquidity and dividend policy and the development of the industries
in which the Company's businesses operate to differ materially from the
impression created by the forward-looking statements. These statements are not
guarantees of future performance and are subject to known and unknown risks,
uncertainties and other factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements.
Given those risks and uncertainties, prospective investors are cautioned not
to place undue reliance on forward-looking statements.

 

These forward-looking statements speak only as at the date of this
announcement and cannot be relied upon as a guide to future performance. Each
of the Company, Cavendish and Deutsche Numis expressly disclaims any
obligation or undertaking to update or revise any forward-looking statements
contained herein to reflect actual results or any change in the assumptions,
conditions or circumstances on which any such statements are based unless
required to do so by the Financial Conduct Authority, the London Stock
Exchange or applicable law.

 

The information in this announcement is for background purposes only and does
not purport to be full or complete. None of Cavendish, Deutsche Numis or any
of their respective affiliates, accepts any responsibility or liability
whatsoever for, or makes any representation or warranty, express or implied,
as to this announcement, including the truth, accuracy or completeness of the
information in this announcement (or whether any information has been omitted
from the announcement) or any other information relating to the Company or
associated companies, whether written, oral or in a visual or electronic form,
and howsoever transmitted or made available or for any loss howsoever arising
from any use of the announcement or its contents or otherwise arising in
connection therewith. Each of Cavendish, Deutsche Numis and their respective
affiliates, accordingly disclaims all and any liability whether arising in
tort, contract or otherwise which it might otherwise be found to have in
respect of this announcement or its contents or otherwise arising in
connection therewith.

 

Any indication in this announcement of the price at which the Ordinary Share
have been bought or sold in the past cannot be relied upon as a guide to
future performance. Persons needing advice should consult an independent
financial adviser. No statement in this announcement is intended to be a
profit forecast and no statement in this announcement should be interpreted to
mean that earnings or target dividend per share of the Company for the current
or future financial years would necessarily match or exceed the historical
published earnings or dividends per share of the Company.

 

Neither the content of the Company's website (or any other website) nor the
content of any website accessible from hyperlinks on the Company's website (or
any other website) is incorporated into or forms part of this announcement.
The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will
not be admitted to trading on any stock exchange other than London Stock
Exchange.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIBDGDSGDGSX